Phase II study of liposomal doxorubicin and gemcitabine in the salvage treatment of ovarian cancer

British Journal of Cancer

Volumn 89, Issue 7, 2003, Pages 1180-1184

  D'Agostino, G ^a   Ferrandina, G ^a   Ludovisi, M ^a   Testa, A ^a   Lorusso, D ^a   Gbaguidi, N ^a   Breda, E ^b   Mancuso, S ^a   Scambia, G ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b FATEBENEFRATELLI HOSPITAL   (Italy)

Author keywords

Gemcitabine; Liposomal doxorubicin; Ovarian cancer

Indexed keywords

DOXORUBICIN; DOXORUBICIN DERIVATIVE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN; METOCLOPRAMIDE; PLATINUM DERIVATIVE; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DRUG ACTIVITY; EVALUATION; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; NAUSEA; NEUTROPENIA; OVARY CANCER; PARESTHESIA; PHASE 2 CLINICAL TRIAL; POPULATION RESEARCH; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENT DISEASE; SALVAGE THERAPY; STATISTICAL ANALYSIS; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DOXORUBICIN; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LIPOSOMES; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 0242266498     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601284     Document Type: Article

References (35)

1. Albrecht GL, Devlieger PJ (1999) The disability paradox: high quality of life against all odds. Soc Sci Med 48: 977 - 988
2. Bajetta E, Di Leo A, Biganzoli L, Mariani L, Capuzzo F, Di Bartolomeo M, Zilembo N, Artale S, Magnani E, Celio L, Buzzoni R, Carnaghi C (1996) Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease. J Clin Oncol 14: 2546 - 2551
3. Berek JS, Bertelsen K, du Bois A, Brady MF, Carmichael J, Eisenhauer EA, Gore M, Grenman S, Hamilton TC, Hansen SW, Harper PG, Horvath G, Kaye SB, Luck HJ, Lund B, McGuire WP, Neijt JP, Ozols RF, Parmar MK, Piccart-Gebhart MJ, van Rijswijk R, Rosenberg P, Rustin GJ, Sessa C, Willemse PH, Thigpen JT, Trope C, Tuxen K, Vergote I, Vermorken JB (1999) Advanced epithelial ovarian cancer: 1998 consensus statements. Ann Oncol 10(Suppl 1): 87 - 92
4. Bookman MA (1999) Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy. Oncologist 4(2): 87 - 94
5. Cannistra SA (2002) Is there a "best" choice of second line agent in the treatment of recurrent, potentially platinum-sensitive ovarian cancer? J Clin Oncol 20: 1158 - 1160
6. Cesano A, Lane SR, Poulin R, Ross G, Fields SZ (1999) Stabilization of disease as a useful predictor of survival following second-line chemotherapy in small cell lung cancer and ovarian cancer patients. Int J Oncol 15: 1233 - 1238
7. Chow KU, Ries J, Weidmann E, Pourebrahim F, Napieralski S, Stieler M, Boehrer S, Rummel MJ, Stein J, Hoelzer D, Mitrou PS (2000) Induction of apoptosis using 2′,2′difluorodeoxycytidine (gemcitabine) in combination with antimetabolites or anthracyclines on malignant lymphatic and myeloid cells. Antagonism or synergism depends on incubation schedule and origin of neoplastic cells. Ann Hematol 79: 485 - 492
8. Colombo N, Parma G, Bocciolone L, Sideri M, Franchi D, Maggioni A (1999) Role of chemotherapy in relapsed ovarian cancer. Crit Rev Oncol/ Hematol 32: 221 - 228
9. D'Agostino G, Ferrandina G, Garganese G, Salerno MG, Lorusso D, Farnetano MG, Mancuso S, Scambia G (2002a) Phase I study of gemcitabine and liposomal doxorubicin in relapsed ovarian cancer. Oncology 62: 110 - 114
10. D'Agostino G, Ludovisi M, Ferrandina G, Lorusso D, Testa A, Carrato P, Salerno MG, Mancuso S, Scambia G (2002b) The liposomal doxorubicin (CAE) and gemcitabine (Gem) is active in relapsed ovarian cancer. A phase II study. Proc Am Soc Clin Oncol 21: A875
11. Dizon D, Hensley M, Sabbatini P, Poynor E, Hummer A, Venkatraman E, Spriggs D (2001) Carboplatin and paclitaxel as initial second-line therapy in recurrent epithelial ovarian carcinoma. Proc Am Soc Clin Oncol 20: A809
12. Gordon AN, Granai CO, Rose PG, Hainsworth J, Lopez A, Weissman C, Resales R, Sharpington T (2000) Phase II study of liposomal doxorubicin in platinum-and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol 18: 3093 - 3100
13. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ (2001) Recurrent epithelial ovarian carcinoma: a randomised phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19: 3312 - 3322
14. Hansen SW, Tuxen MK, Sessa C (1999) Gemcitabine in the treatment of ovarian cancer. Ann Oncol 10(S1): 51 - 53
15. Jemal A, Murray T, Samuels A, Ghafoor A, Word E, Thun M (2003) Cancer statistics, 2003. CA Cancer J Clin 53: 5 - 26
16. Markman M, Rothman R, Hakes T, Reichman B, Hoskins W, Rubin S, Jones W, Almadrones L, Lewis Jr JL (1991) Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 9: 389 - 393
17. Markman M (2002) Second-line treatment of ovarian cancer with single-agent gemcitabine. Semin Oncol 29(S1): 9 - 10
18. Mathe G, Reizenstein P (1986) Ethics and errors of clinical trials and the role and place of trial. Drugs Exp Clin Res 12(1-3): 1 - 9
19. National Cancer Institute Common Toxicity Criteria (1998), Version 2.0. Revised March 23, http://ctep.info.nih.gov/CTC3/default.htm
20. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: 649 - 655
21. Ozer H, Armitage JO, Bennett CL, Crawford J, Demetri GD, Pizzo PA, Shiffer CA, Smith TJ, Somlo G, Wade JC, Wade III JL, Winn RJ, Wozniak AJ, Somerfield MR (2000) 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 18: 3558 - 3585
22. Ozols RF (1997) Treatment of recurrent ovarian cancer: increasing options-"recurrent" results. J Clin Oncol 15: 2177 - 2180
23. Ozols RF (2000) Management of advanced ovarian cancer consensus summary. Semin Oncol 27(S2): 47 - 49
24. Ozols RF (2002a) Recurrent ovarian cancer: evidence-based treatment. J Clin Oncol 20: 1161 - 1163
25. Ozols RF (2002b) Future directions in the treatment of ovarian cancer. Semin Oncol 29(S1): 32 - 42
26. Rizzo JD, Lichtin AE, Woolf SH, Seidenfeld J, Bennett CL, Cella D, Djulbegovich B, Goode MJ, Jakubowski AA, Lee SJ, Miller CB, Rarick MU, Regan DH, Browman GP, Gordon MS (2002) Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 19: 4083 - 4107
27. Rose PG, Blessing JA, Mayer AR, Homesley HD (1998) Prolonged oral etoposide as second line therapy for platinum-resistant and platinum sensitive ovarian carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 16: 405 - 410
28. Sabbatini P, Aghajanian C, Spriggs D (1998) Chemotherapy in gynecologic cancers. Curr Opin Oncol 10: 429 - 433
29. Safra T, Groshen S, Jeffers S, Tsao-Wei DD, Zhou L, Muderspach L, Roman L, Morrow P, Burnett A, Muggia FM (2001) Treatment of patients with ovarian carcinoma with pegylated liposomal doxorubicin. Cancer 91: 90 - 100
30. Shapiro JD, Millward MJ, Rischin D, Michael M, Walcher V, Francis PA, Toner GC (1996) Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecol Oncol 63: 89 - 93
31. Sprangers MAG, Schwartz CE (1999) Integrating response shift into health-related quality of life research: a theoretical model. Soc Sci Med 48: 1507 - 1515
32. Ten Bokkel Huinink W, Gore M, Carmichael J, Gordon A, Malfetano J, Hudson I, Broom C, Scarabelli C, Davidson N, Spariczynski M, Bolis G, Malmstrom H, Coleman R, Fields SC, Heron JF (1997) Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 15: 2183 - 2193
33. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92: 205 - 216
34. Zanotti KM, Belinson JL, Kennedy AW, Webster KD, Markman M (2000) Treatment of relapsed carcinoma of the ovary with single agent paclitaxel following exposure to paclitaxel and platinum employed as initial therapy. Gynecol Oncol 79: 211 - 215
35. Zoli W, Ricotti L, Barzanti F, Dal Susino M, Frassineti GL, Milandri C, Casadei Giunchi D, Amadori D (1999) Schedule-dependent interaction of doxorubicin, paclitaxel and gemcitabine in human breast cancer cell lines. Int J Cancer 80; 413 - 416